Evidence map›Paper›PMID 42666428›Full record

ArticleResearch (Washington, D.C.)2026

Programmed Probiotics Generate Interleukin-37b-Bearing Nanovesicles In Situ for Precision Immunomodulation in Colitis.

Xiaojing Zhang, Liufei Gong, Haiyi Zhang, Yang Luo, Tengfei Long, Qian He, Yang Luo, Lu Han, Zhipeng Li, Cang Li and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Research (Washington, D.C.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Xiaojing ZhangState Key Laboratory of Animal Disease Control and Prevention, South China Agricultural University, Guangzhou, China.
Liufei GongState Key Laboratory of Animal Disease Control and Prevention, South China Agricultural University, Guangzhou, China.
Haiyi ZhangState Key Laboratory of Animal Disease Control and Prevention, South China Agricultural University, Guangzhou, China.
Yang LuoState Key Laboratory of Animal Disease Control and Prevention, South China Agricultural University, Guangzhou, China.
Tengfei LongState Key Laboratory of Animal Disease Control and Prevention, South China Agricultural University, Guangzhou, China.
Qian HeState Key Laboratory of Animal Disease Control and Prevention, South China Agricultural University, Guangzhou, China.
Yang LuoState Key Laboratory of Animal Disease Control and Prevention, South China Agricultural University, Guangzhou, China.
Lu HanState Key Laboratory of Animal Disease Control and Prevention, South China Agricultural University, Guangzhou, China.
Zhipeng LiState Key Laboratory of Animal Disease Control and Prevention, South China Agricultural University, Guangzhou, China.
Cang LiState Key Laboratory of Animal Disease Control and Prevention, South China Agricultural University, Guangzhou, China.
Xiaoyu WangState Key Laboratory of Animal Disease Control and Prevention, South China Agricultural University, Guangzhou, China.
Zijian ZhengState Key Laboratory of Animal Disease Control and Prevention, South China Agricultural University, Guangzhou, China.
Yao DengState Key Laboratory of Animal Disease Control and Prevention, South China Agricultural University, Guangzhou, China.
Xiaoping LiaoState Key Laboratory of Animal Disease Control and Prevention, South China Agricultural University, Guangzhou, China.
Hao RenState Key Laboratory of Animal Disease Control and Prevention, South China Agricultural University, Guangzhou, China.
Jian SunState Key Laboratory of Animal Disease Control and Prevention, South China Agricultural University, Guangzhou, China.ORCID https://orcid.org/0000-0002-4209-7555

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Genetically engineered probiotic bacteria are promising living therapeutics. However, their therapeutic potential is frequently confined to their colonization sites, and limitations in efficacy, controllability, and robustness remain major barriers to translation. Anti-inflammatory cytokines play a crucial role in mitigating the pathogenesis of inflammation-related diseases, yet their application is limited by their vulnerability in the mammalian gastrointestinal tract. In this regard, we first found that interleukin-37b (IL-37b) mitigated inflammatory responses at picogram concentrations in primary intestinal cells, supporting its translational potential for the oral treatment of inflammatory diseases. Then, we harnessed the probiotic bacterium

Identifiers

PMID42666428
PMCPMC13522564

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.